We tested the following hypotheses: (a) that CD362+ UC-hMSCs would be as effective as standard BM and UC-derived hMSCs in attenuating E. coli pneumonia, (b) there is a therapeutic limit to the passaging of the hMSC, (c) CD362+ UC-hMSCs would prove effective in antibiotic treated pneumonia, (d) cryopreservation of CD362+ UC-hMSCs would retain efficacy, and (e) that delayed therapy with CD362+ UC-hMSCs would be effective in E. coli pneumonia. This evidence concerns the gene SDC2 and pneumonia.